RVL Pharmaceuticals plc Debt Instrument, Fair Value Disclosure
RVL Pharmaceuticals plc had Debt Instrument, Fair Value Disclosure of $57.75 million as of 2023-06-30, per its 10-Q filed 2023-08-14.
Discontinued › Notes › Debt › Debt Instruments
us-gaap:DebtInstrumentFairValue · last filed 2023-08-14
- 2023-06-30: Debt Instrument, Fair Value Disclosure $57.75M.
- 2023-03-31: Debt Instrument, Fair Value Disclosure $57.19M.
- 2022-12-31: Debt Instrument, Fair Value Disclosure $56.93M.
- 2022-09-30: Debt Instrument, Fair Value Disclosure $55.90M.
| Period end | Debt Instrument, Fair Value Disclosure |
|---|---|
| 2023-06-30 | $57.75M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $57.19M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $56.93M 10-Q · filed 2023-08-14 |
| 2022-09-30 | $55.90M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $43.51M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $46.61M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $46.21M 10-K · filed 2023-03-20 |
| 2020-12-31 | $219.53M 10-K · filed 2022-03-30 |